Document Detail

Lysis of autologous tumor cells by peripheral blood lymphocytes treated with interleukin 2 in patients with renal cell carcinoma.
MedLine Citation:
PMID:  3494137     Owner:  NLM     Status:  MEDLINE    
Peripheral blood lymphocytes derived from patients with renal cell carcinoma were stimulated with interleukin 2 and tested in a 4-hour 51chromium-release cytotoxicity assay against autologous cultured tumor and myeloid K562 cells. Of 23 patients autologous tumor lysis of more than 0 per cent was observed in 20 (range 5.3 to 82.8 per cent) and more than 10 per cent lysis was noted in 16. Since no significant correlation between the degree of cytotoxicity and the pathological findings of tumor stage, grade, cell type or lymphocyte infiltration in the tumor was found, it was impossible to predict from the pathological findings which tumor could be lysed by peripheral blood lymphocytes treated with interleukin 2. Comparison of natural killer cell activity against K562 of freshly prepared peripheral blood lymphocytes to that of interleukin 2-treated lymphocytes revealed significant augmentation from 23.6 +/- 9.7 to 65.2 +/- 29.1 per cent. From the kinetics study the lysis of autologous tumor cells was detectable on day 2 of interleukin 2 exposure and the peak activity was observed on day 5. A similar trend was noted in regard to K562 cell lysis. Measurements of peripheral blood lymphocyte subsets with monoclonal antibodies and argon ion laser flow cytometry resulted in a significant decrease of cells positive for OKT 4 (helper/inducer) and a significant increase of cells positive for OKT 8 (suppressor/cytotoxic) and Leu 7 (natural killer) by interleukin 2 treatment. A cold target cell inhibition test was performed in 2 patients with unlabeled autologous tumor and K562 cells as cold inhibitors. In 1 patient unlabeled K562 completely inhibited the tumor lysis but in 1 complete inhibition by autologous tumor and incomplete blockade by K562 were found. From this observation we concluded that peripheral blood lymphocytes treated with interleukin 2 lysed not only autologous tumor cells but also K562. Our results demonstrate that adoptive immunotherapy with peripheral blood lymphocytes activated by interleukin 2 in patients with renal cell carcinoma could be appropriate as a therapeutic procedure.
E Nakano; Y Tada; Y Ichikawa; H Fujioka; M Matsuda; M Takaha; T Sonoda
Related Documents :
8477417 - Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (il-2) and tumo...
17056587 - Gene transfer of tumor-reactive tcr confers both high avidity and tumor reactivity to n...
24647337 - Effects of curcumin analogues for inhibiting human prostate cancer cells and the growth...
6334137 - Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma an...
270747 - Reduction of syngeneic tumor growth by an anti-i-j-alloantiserum.
11370557 - Radiotherapeutic response of ehrlich ascites tumor cells perfused in agarose gel thread...
Publication Detail:
Type:  In Vitro; Journal Article    
Journal Detail:
Title:  The Journal of urology     Volume:  137     ISSN:  0022-5347     ISO Abbreviation:  J. Urol.     Publication Date:  1987 Apr 
Date Detail:
Created Date:  1987-04-27     Completed Date:  1987-04-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0376374     Medline TA:  J Urol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  641-8     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Carcinoma, Renal Cell / blood,  immunology*
Cytotoxicity Tests, Immunologic
Interleukin-2 / immunology*
Kidney Neoplasms / blood,  immunology*
Lymphocyte Activation / drug effects*
Middle Aged
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nutritional and socio-demographic risk indicators of malaria in children under five: a cross-section...
Next Document:  T-lymphocyte subsets in primary lung cancer.